Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.

After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering.

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

Obesity-drug developer BioAge Labs Inc. gained nearly 30% after its initial public offering on Thursday, while natural-gas producer BKV Inc.'s rose about 3% over its $18 IPO price. BioAge (BIOA) stock ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

(Reuters) - Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday. As the ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Obesity-drug developer BioAge held on to a slim gain after rising more than 20%, while Texas-based Barnett Shale driller BKV ...